Westboy
2021-08-17

On Aug. 12, the FDA updated the Emergency Use Authorizations (EUAs) for the COVID-19 vaccines made by Pfizer (NYSE:PFE) along with its partner, BioNTech (NASDAQ:BNTX), and Moderna (NASDAQ:MRNA) to include a third booster dose for immunocompromised individuals. One day later, the CDC changed its stance to recommend booster doses of the two messenger RNA (mRNA) vaccines for moderately to severely immunocompromised individuals.

With EUAs in hand for third booster doses, will the top COVID-19 vaccine makers rake in a lot more revenue now? Not really. Here's why Pfizer and Moderna won't make as much extra money from U.S. booster doses as you might think.

One key reason why Pfizer and Moderna won't make much more money is the limited scope of the EUA expansions. The FDA said that the broader authorizations will permit booster doses for "solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise."

Acting FDA Commissioner Janet Woodcock stated, "After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna Vaccines." Her wording clearly indicates that the target group for booster doses isn't very large.

Just how big is the opportunity for Pfizer and Moderna? Around 3% of U.S. adults are moderately to severely immunocompromised, according to the CDC. That's around 8 million people.

Using the $24 per dose price for the Pfizer-BioNTech COVID-19 vaccine, this market is in the ballpark of $190 million. And it will be divided between Pfizer and Moderna. Pfizer expects its COVID-19 vaccine will generate $33.5 billion in sales this year. Moderna projects around $20 billion in sales for its vaccine. The U.S. booster dose market under the current expanded EUAs represents under 1% of those totals.


Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • Ireneteo
    2021-08-20
    Ireneteo
    How many boosters required???
  • Hanu
    2021-08-23
    Hanu
    As i told before this stock price Can go up to 100$+ very soon due to FDA approval and third dose confirmation.
  • Ag1718
    2021-08-29
    Ag1718
    ?☀️ Positive thinking is more than just a tagline. It changes the way we behave. And I firmly believe that when I am positive. It not only makes me better , but it also make those around me better.
  • Hanu
    2021-08-23
    Hanu
    May be 2-3 boosters required , until China disclosed the actial root cause for this COVID or USA finds the permanent vaccine.
  • Ag1718
    2021-08-27
    Ag1718
    ?? ..when Stock go up we ,will Be greedy and greedy ..only when other are fearful we will be fearful too .


    Just relax ???..


    Happy day ☀️???
  • 田青
    2021-08-25
    田青
    不忘初心牢记使命
Leave a comment
64
10